京新药业(002020) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥793,742,204.43, a decrease of 11.15% compared to ¥893,372,399.42 in the same period last year[9] - Net profit attributable to shareholders was ¥95,666,199.21, down 27.18% from ¥131,379,249.16 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥79,533,640.22, a decrease of 15.60% compared to ¥94,231,955.93 in the previous year[9] - Basic and diluted earnings per share were both ¥0.1329, down 29.87% from ¥0.1895 in the previous year[9] - Total revenue for the current period is ¥793,742,204.43, a decrease of 11.2% compared to ¥893,372,399.42 in the previous period[76] - Net profit for the current period is ¥96,502,982.74, a decrease of 26.7% from ¥131,530,009.98 in the previous period[83] - Operating profit decreased to ¥76,490,200.26, down 34.7% from ¥117,331,987.97 in the previous period[87] - Total comprehensive income for the current period is ¥69,585,952.89, compared to ¥105,784,721.57 in the previous period[90] Cash Flow - The net cash flow from operating activities increased by 76.02% to ¥121,862,146.77 from ¥69,232,593.75 in the same period last year[9] - Cash flow from operating activities generated a net amount of ¥121,862,146.77, an increase of 76.2% from ¥69,232,593.75 in the previous period[91] - Net cash flow from financing activities increased by 3762.44% to ¥227,635,340.82, primarily due to an increase in cash received from borrowings[40] - Financing activities generated a net cash inflow of ¥227,635,340.82, compared to a net outflow of ¥6,215,408.54 in the previous period[97] - Investment activities resulted in a net cash outflow of ¥278,056,622.69, worsening from a net outflow of ¥100,485,380.69 in the previous period[94] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,841,770,264.99, an increase of 3.85% from ¥5,625,088,046.03 at the end of the previous year[9] - Total liabilities increased to CNY 2,105,001,046.32 from CNY 1,914,376,310.28, representing a growth of about 9.93%[64] - Total current liabilities amounted to CNY 1,961,932,464.72, an increase from CNY 1,770,292,227.81, reflecting a growth of about 10.80%[64] - Total assets amounted to CNY 4,862,688,352.78, with current assets at CNY 2,544,359,556.59 and non-current assets at CNY 2,318,328,796.19[111] Shareholder Equity - Net assets attributable to shareholders were ¥3,722,181,288.11, a slight increase of 0.71% from ¥3,696,079,802.35 at the end of the previous year[9] - The company's equity attributable to shareholders reached CNY 3,722,181,288.11, up from CNY 3,696,079,802.35, an increase of approximately 0.71%[67] - The company has a total of CNY 3,710,711,735.75 in total equity, including minority interests of CNY 14,631,933.40[108] Expenses - Total operating costs for the current period are ¥707,217,154.49, down 8.7% from ¥774,883,655.75 in the previous period[79] - Research and development expenses for the current period are ¥66,227,053.39, an increase from ¥51,043,288.08 in the previous period[79] - The company reported a decrease in sales expenses to ¥159,789,393.41, down 1.1% from ¥161,588,371.99 in the previous period[87] Other Financial Metrics - The weighted average return on equity decreased by 1.04 percentage points to 2.63% from 3.67% in the previous year[9] - The company reported a non-operating income of ¥16,132,558.99 during the reporting period[9] - Other income increased by 144.26% to ¥14,124,151.09, primarily due to an increase in government subsidies[31] - The company received 200,000,000.00 CNY in loans during the financing activities, indicating a reliance on debt financing[101] Miscellaneous - The company established a wholly-owned subsidiary in Shandong Province with an investment of ¥12,000,000 to promote the orderly implementation of the Weifang project[42] - The first quarter report for 2020 was not audited[114]